Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity.
Francisco Fellipe Claudino FormigaClovis Artur SilvaTatiana do Nascimento PedrosaNádia Emi AikawaSandra Gofinet PasotoCristiana Couto GarciaArtur Silva Vidal CapãoVictor Adriano de Oliveira MartinsAdriana Coracini Tonacio de ProençaRicardo FullerEmily Figueiredo Neves YukiMargarete Borges Galhardo VendraminiDebora Cordeiro do RosárioLeticia Maria Kolachinski Raposo BrandãoAna Marli Christovam SartoriLeila AntonangeloEloisa S BonfaEduardo Ferreira BorbaPublished in: Lupus (2021)
Influenza A/Singapore (H3N2) vaccine has an adequate safety profile. The distinct immunogenicity pattern from other influenza A components characterized by a remarkably high pre- and post-vaccination SP rate and high GMT levels may be associated with previous influenza A vaccination. (www.clinicaltrials.gov, NCT03540823).
Keyphrases